Skip to Content

Generic Eliquis Availability

Eliquis is a brand name of apixaban, approved by the FDA in the following formulation(s):

ELIQUIS (apixaban - tablet;oral)

Has a generic version of Eliquis been approved?

A generic version of Eliquis has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Eliquis and have been approved by the FDA:

apixaban tablet;oral

  • Manufacturer: BIONPHARMA INC
    Approval date: April 8, 2020
    Strength(s): 2.5MG [AB], 5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eliquis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
    Patent 6,967,208
    Issued: November 22, 2005
    Inventor(s): Pinto; Donald J. P. & Quan; Mimi L. & Orwat; Michael J. & Li; Yun-Long & Han; Wei & Qiao; Jennifer X. & Lam; Patrick Y. S. & Koch; Stephanie L.
    Assignee(s): Bristol-Myers Squibb Pharma Company

    The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

    Patent expiration dates:

    • November 21, 2026
      ✓ 
      Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 21, 2026
      ✓ 
      Patent use: REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 21, 2026
      ✓ 
      Patent use: TREATMENT OF PULMONARY EMBOLISM (PE)
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 21, 2026
      ✓ 
      Patent use: REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 21, 2026
      ✓ 
      Patent use: REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 21, 2026
      ✓ 
      Patent use: TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 21, 2026
      ✓ 
      Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 21, 2026
      ✓ 
      Patent use: REDUCING THE RISK OF STROKE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 21, 2026
      ✓ 
      Patent use: PROPHYLAXIS OF PULMONARY EMBOLISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Apixaban formulations
    Patent 9,326,945
    Issued: May 3, 2016
    Assignee(s): Bristol-Myers Squibb Company Pfizer Inc.

    Compositions comprising crystalline apixaban particles having a D90 equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

    Patent expiration dates:

    • February 24, 2031
      ✓ 
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.